Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response

PURPOSE: Some chemotherapeutics have been shown to induce both the release of damage-associated molecular patterns (DAMPs) and the production of type I interferon (IFN-I), leading to immunogenic cell death (ICD). However, the standard chemotherapy drug for glioma, temozolomide (TMZ), cannot induce I...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Peidi, Li, Huifeng, Ke, Chao, Cao, Guangxu, Xin, Xiaoqian, Hu, Junjiao, Cai, Xiangran, Li, Lingfeng, Liu, Xiaowen, Du, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065718/
https://www.ncbi.nlm.nih.gov/pubmed/32189965
http://dx.doi.org/10.2147/IJN.S240551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065718/
https://www.ncbi.nlm.nih.gov/pubmed/32189965
http://dx.doi.org/10.2147/IJN.S240551

Ejemplares similares